NKF's subsidiary Kindos’s self-developed Ropivacaine Hydrochloride Injection gets FDA approval for marketing
This once again fully demonstrates Kindos team the professional and efficient R&D capability, the international first-class cGMP manufacturing capability and the precise and rigorous pharmaceutical registration capability.
